Literature DB >> 17705231

Monoclonal anti-A antibody removal by synthetic A antigen immobilized on specific antibody filters.

Shalini Gautam1, Elena Y Korchagina, Nicolai V Bovin, William J Federspiel.   

Abstract

Removal of blood group anti-A and anti-B antibodies can prevent hyperacute organ rejection in ABO-incompatible transplantation. We are developing an extracorporeal-specific antibody filter (SAF) as an immunoadsorption device for direct removal of ABO blood group antibodies from whole blood, without the need for plasma separation and plasma exchange. A hollow fiber-based small scale SAF (mini-SAF) device was fabricated and synthetic A antigen, Atrisaccharide (Atri) conjugated to activated polyacrylic acid, was immobilized on the fiber lumen surface. Monoclonal antibody anti-A IgM were specifically removed up to 70% of initial antibodies using mini-SAF device. The monoclonal anti-A capture experiments on mini-SAF indicated that antibody removal relative to the initial concentration is independent of inlet concentration in the beginning; however, as the surface starts saturating with bound antibodies, removal becomes dependent on inlet concentration. No significant effect of flow rate on removal rate was observed. The radial diffusion and axial convection-based mathematical model developed for unsteady state antibody removal was in good agreement with the experimental data and showed that the antibody removal rate can be maximized by increasing the antibody-binding capacity of the SAF. Copyright 2007 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17705231     DOI: 10.1002/bit.21621

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  1 in total

1.  High molecular weight blood group A trisaccharide-polyacrylamide glycoconjugates as synthetic blood group A antigens for anti-A antibody removal devices.

Authors:  Azadeh Alikhani; Elena Y Korchagina; Alexander A Chinarev; Nicolai V Bovin; William J Federspiel
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2009-11       Impact factor: 3.368

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.